Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NEIL1
REST API REST API
Homo sapiens
NEIL1 is differentially expressed in 188 experiments: 91 organism parts: lung, tonsil, ... (89 more);, 129 disease states: normal, Daudi Burkitt's lymphoma, ... (127 more);, 54 cell types 236 cell lines 19 compound treatments and 64 other conditions.
Synonyms hFPG1, FLJ22402, NEI1, FPG1
Orthologs NEIL1 (Bos taurus)   NEIL1 (Gallus gallus)   Neil1 (Mus musculus)   neil1 (Danio rerio)   Neil1 (Rattus norvegicus)   neil1 (Xenopus laevis)   NEIL1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to oxidative stress, nucleotide-excision repair, DNA repair, cytoplasm, damaged DNA binding, DNA-(apurinic or apyrimidinic site) lyase activity, hydrolase activity, acting on glycosyl bonds, lyase activity, nucleus, hydrolase activity, hydrolyzing N-glycosyl compounds, protein C-terminus binding, base-excision repair, zinc ion binding, negative regulation of nuclease activity, DNA N-glycosylase activity
InterPro Term DNA_glyclase/AP_lyase_DNA-bd, DNA_glycosylase/AP_lyase_cat, Endonuclease-VIII_DNA-bd
UniProt Accession Q96FI4
Search EB-eye ENSG00000140398
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-803, E-GEOD-6573, E-MEXP-1251, ... (18 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (26 experiments)

Factor Value U/D Experiments
BT474
2
E-MEXP-440, E-MTAB-37
AGS
2
E-MTAB-37, E-GEOD-15460
A549
2
E-GEOD-6013, E-GEOD-3202
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-7
2
E-GEOD-20081, E-GEOD-3529
NA19093
1
E-GEOD-19480
230 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-22373, E-GEOD-21668, E-MEXP-120, E-MEXP-66, ... (31 experiments)

Factor Value U/D Experiments
macrophage
2
E-GEOD-22373, E-GEOD-3982
memory B cell
1
E-TABM-702
hematopoietic stem cell
1
E-MEXP-1403
not specified
1
E-GEOD-18811
primary lymphatic endothelial cell
1
E-MEXP-66
B lymphocyte
1
E-GEOD-6691
48 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-22529, E-GEOD-1869, E-GEOD-1577, ... (48 experiments)

Factor Value U/D Experiments
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
myeloma
1
E-MTAB-372
FAB: M1 acute myeloid leukemia
1
E-GEOD-12662
calpainopathy
1
E-MTAB-62
meningitis
1
E-MTAB-62
123 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-15205, E-GEOD-5824, E-GEOD-3720, E-MEXP-1958, ... (14 experiments)

Factor Value U/D Experiments
none
1
4
E-MEXP-1958, E-GEOD-5824, E-MEXP-1601, E-GEOD-4668, E-MEXP-1230 ... (5 experiments)
HMB-PP (phosphoantigen)
1
E-MEXP-1601
17beta-estradiol
3
1
E-GEOD-4668
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
unknown
1
E-GEOD-7307
placebo
1
E-MEXP-1327
13 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-19246, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-MEXP-2283, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-1561, E-GEOD-19665

Environmental stress
studied in E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-3494, E-MEXP-421, E-TABM-43, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-20540, E-MEXP-1273, E-MEXP-2146, E-GEOD-20505

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-GEOD-19330, E-TABM-666, ... (19 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561

Initial distant metastases
studied in E-GEOD-22541

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1460, E-MEXP-1403

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-MEXP-101, E-MEXP-548, E-GEOD-3697, E-MEXP-2759

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276, E-GEOD-2748

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-13818, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-TABM-43, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.43 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM